Triple negative tumours: a critical review

Histopathology - Tập 52 Số 1 - Trang 108-118 - 2008
JS Reis‐Filho1, Andrew Tutt2,3
1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
2The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London
3the Breakthrough Breast Cancer Unit at Kings College London, Guy’s Hospital, London, UK

Tóm tắt

Breast cancer is a heterogeneous disease that encompasses several distinct entities with remarkably different biological characteristics and clinical behaviour. Currently, breast cancer patients are managed according to algorithms based on a constellation of clinical and histopathological parameters in conjunction with assessment of hormone receptor (oestrogen and progesterone receptor) status and HER2 overexpression/gene amplification. Although effective tailored therapies have been developed for patients with hormone receptor‐positive or HER2+ disease, chemotherapy is the only modality of systemic therapy for patients with breast cancers lacking the expression of these markers (triple‐negative cancers). Recent microarray expression profiling analyses have demonstrated that breast cancers can be systematically characterized into biologically and clinically meaningful groups. These studies have led to the re‐discovery of basal‐like breast cancers, which preferentially show a triple‐negative phenotype. Both triple‐negative and basal‐like cancers preferentially affect young and African‐American women, are of high histological grade and have more aggressive clinical behaviour. Furthermore, a significant overlap between the biological and clinical characteristics of sporadic triple‐negative and basal‐like cancers and breast carcinomas arising in BRCA1 mutation carriers has been repeatedly demonstrated. In this review, we critically address the characteristics of basal‐like and triple‐negative cancers, their similarities and differences, their response to chemotherapy as well as strategies for the development of novel therapeutic targets for these aggressive types of breast cancer. In addition, the possible mechanisms are discussed leading to BRCA1 pathway dysfunction in sporadic triple‐negative and basal‐like cancers and animal models for these tumour types.

Từ khóa


Tài liệu tham khảo

10.1016/j.prp.2005.05.013

10.1677/erc.1.00758

10.1002/path.1691

10.1038/35021093

10.1073/pnas.191367098

10.1073/pnas.0932692100

10.1136/jcp.2005.028324

10.1200/JCO.2005.03.3845

10.1158/1078-0432.CCR-04-2421

10.1158/1078-0432.CCR-04-0220

10.1016/S0002-9440(10)64476-8

10.1186/bcr1636

10.1097/01.pas.0000213306.05811.b9

10.1158/1078-0432.CCR-06-1109

10.1186/bcr1041

10.1186/bcr260

10.1073/pnas.96.22.12589

10.1158/0008-5472.CAN-03-2028

10.1007/s00428-005-0010-7

10.1007/s10549-006-9184-1

10.1186/1471-2164-7-96

10.1002/ijc.21004

Savage K, 2007, Distribution and significance of Caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis, Breast Cancer Res. Treat.

10.1186/bcr1517

10.1007/s10549-006-9492-5

10.1186/bcr1341

10.1111/j.1365-2559.2006.02467.x

10.1002/(SICI)1096-9896(199608)179:4<386::AID-PATH631>3.0.CO;2-V

10.1007/s004280050226

10.1016/S0140-6736(87)92129-5

10.1007/978-3-662-30514-0_3

Gould VE, 1990, Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast, Am. J. Pathol., 137, 1143

10.1002/path.1711570406

10.1073/pnas.1732912100

10.1111/j.1365-2559.2006.02453.x

10.1158/1078-0432.CCR-04-2424

10.1038/modpathol.3800528

10.1097/00000478-200002000-00005

10.1016/S0046-8177(99)90028-X

10.1002/path.1845

10.1186/bcr1666

10.1002/path.1559

10.1056/NEJMoa052933

10.1186/bcr1649

10.1158/1078-0432.CCR-05-2281

10.1158/1078-0432.CCR-06-3045

10.1200/JCO.2006.06.5664

10.1002/cncr.22381

10.1186/1471-2407-7-134

10.1002/cncr.22618

10.1186/bcr1622

10.1002/cncr.22836

10.1038/sj.onc.1210014

10.1002/path.1916

10.1136/jcp.56.7.497

10.1002/cncr.11688

Rakha EA, 2007, Basal‐like breast cancer: a critical review, J. Clin. Oncol.

10.1038/labinvest.3700529

10.1038/nrc1457

10.1038/sj.onc.1209876

10.4161/cc.5.9.2726

10.1158/0008-5472.CAN-03-4080

10.1073/pnas.0702955104

10.1038/nm0196-72

10.1016/j.coph.2005.03.006

10.1128/MCB.01229-06

10.1158/0008-5472.CAN-06-1495

10.1002/path.2004

10.1186/1471-2164-8-258

10.1038/modpathol.3800438

10.1200/JCO.2005.01.0793

10.1200/JCO.2006.06.3958

10.1016/S1470-2045(05)70102-9

10.1007/978-3-540-46091-6_12

10.1158/1078-0432.CCR-0597-3

10.1007/s10549-006-9463-x

10.1158/0008-5472.CAN-06-3633

10.1158/1078-0432.CCR-06-1371

10.1038/sj.onc.1209254

10.1007/s10549-006-9184-1

10.1016/0304-419X(96)00003-0

10.1158/0008-5472.CAN-03-2258

10.1158/0008-5472.CAN-03-2970

Vaziri SA, 2001, Breast tumor immunophenotype of BRCA1‐mutation carriers is influenced by age at diagnosis, Clin. Cancer Res., 7, 1937

10.1093/jnci/djg050

10.1002/gcc.20366

10.1158/1078-0432.CCR-03-0731

10.1158/0008-5472.822.65.3

Wessels LF, 2002, Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors, Cancer Res., 62, 7110

10.1093/jnci/92.7.564

10.1177/106689690301100301

10.1007/s10549-004-7603-8

10.1073/pnas.98.1.130

10.1073/pnas.062181799

10.1002/path.2124

10.1073/pnas.0702969104

Yap TA, 2007, First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU‐0059436 (Ku), a small molecule inhibitor of poly ADP‐ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers, J. Clin. Oncol., 25, 3529, 10.1200/jco.2007.25.18_suppl.3529

Thông tin
Thông tin xuất bản

Histopathology

Tập 52 Số 1

108-118

Thông tin tác giả